Circulating Biomarkers for Alzheimer's Disease: Unlocking the Diagnostic Potential in Low- and Middle-Income Countries, Focusing on Africa.
Neurodegener Dis
; 24(1): 26-40, 2024.
Article
em En
| MEDLINE
| ID: mdl-38555638
ABSTRACT
BACKGROUND:
Alzheimer's disease (AD) is emerging as a significant public health challenge in Africa, with predictions indicating a tripling in incidence by 2050. The diagnosis of AD on the African continent is notably difficult, leading to late detection that severely limits treatment options and significantly impacts the quality of life for patients and their families.SUMMARY:
This review focuses on the potential of high-sensitivity specific blood biomarkers as promising tools for improving AD diagnosis and management globally, particularly in Africa. These advances are particularly pertinent in the continent, where access to medical and technical resources is often limited. KEY MESSAGES Identifying precise, sensitive, and specific blood biomarkers could contribute to the biological characterization and management of AD in Africa. Such advances promise to improve patient care and pave the way for new regional opportunities in pharmaceutical research and drug trials on the continent for AD.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Biomarcadores
/
Países em Desenvolvimento
/
Doença de Alzheimer
Limite:
Humans
País/Região como assunto:
Africa
Idioma:
En
Revista:
Neurodegener Dis
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Suíça